What is Leerink Partnrs’ Forecast for VIR Q2 Earnings?

Vir Biotechnology, Inc. (NASDAQ:VIR) – Research analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for shares of Vir Biotechnology in a report released on Sunday, January 12th. Leerink Partnrs analyst R. Ruiz anticipates that the company will post earnings per share of ($0.95) for the quarter. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($3.36) per share. Leerink Partnrs also issued estimates for Vir Biotechnology’s Q3 2025 earnings at ($0.88) EPS and Q4 2025 earnings at ($0.87) EPS.

Several other research firms also recently weighed in on VIR. Needham & Company LLC reiterated a “buy” rating and set a $19.00 target price on shares of Vir Biotechnology in a research report on Wednesday, November 20th. Leerink Partners lifted their target price on Vir Biotechnology from $18.00 to $20.00 and gave the company an “outperform” rating in a research report on Monday. HC Wainwright reiterated a “buy” rating and set a $110.00 target price on shares of Vir Biotechnology in a research report on Friday, January 10th. Morgan Stanley upgraded Vir Biotechnology from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $10.00 to $20.00 in a research report on Thursday, January 9th. Finally, Barclays decreased their price target on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $34.83.

Vir Biotechnology Price Performance

VIR stock opened at $10.50 on Tuesday. The company has a market cap of $1.45 billion, a P/E ratio of -2.68 and a beta of 0.51. Vir Biotechnology has a 1 year low of $6.56 and a 1 year high of $14.45. The stock’s fifty day moving average price is $8.27 and its 200-day moving average price is $8.37.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.51). The firm had revenue of $2.38 million during the quarter, compared to analysts’ expectations of $5.54 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The business’s quarterly revenue was down 9.8% on a year-over-year basis. During the same quarter last year, the business earned ($1.22) earnings per share.

Insider Transactions at Vir Biotechnology

In related news, Director Vicki L. Sato sold 10,960 shares of Vir Biotechnology stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total value of $137,219.20. Following the completion of the transaction, the director now owns 1,312,391 shares in the company, valued at approximately $16,431,135.32. This trade represents a 0.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 14,786 shares of company stock valued at $170,172. 15.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Blue Trust Inc. grew its position in Vir Biotechnology by 143.5% in the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock worth $30,000 after acquiring an additional 2,351 shares in the last quarter. nVerses Capital LLC purchased a new position in Vir Biotechnology in the third quarter worth about $56,000. Magnetar Financial LLC purchased a new position in Vir Biotechnology in the second quarter worth about $95,000. Quest Partners LLC boosted its position in shares of Vir Biotechnology by 142.1% during the second quarter. Quest Partners LLC now owns 12,695 shares of the company’s stock valued at $113,000 after buying an additional 7,452 shares during the period. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Vir Biotechnology during the second quarter valued at approximately $119,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).